Earnings
Galapagos NV announces its unaudited Q3 results, which are further detailed in its Q3 2018 report available on the Galapagos website, www.glpg.com.
Biopharma companies set to release financial reports next week have reported positive news in recent months.
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
Cash and cash equivalents of €219.9 million at September 30, 2018
Start of pivotal US prostate cancer study and treatment of first patients with NanoTherm therapy following U.S. FDA IDE approval in February and IRB approvals in April of this year
Regeneus Ltd provides the Company’s quarterly results for the period ended 30 September 2018.
Cash position of EUR 44.2 million as of September 30, 2018
October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month.
It may not have always felt like it, but biotech has been in a bull market mode over the past two-and-a-half years, ever since the iShares Biotechnology Index (IBB) bottomed out at $80.01 on February 9, 2016.
After providing an update of its ongoing strategic review, New York-based Synergy Pharmaceuticals’ stock plunged more than 71 percent.
PRESS RELEASES